Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Depression: HELP
Articles from Duke University
Based on 980 articles published since 2010
||||

These are the 980 published articles about Depression that originated from Duke University during 2010-2020.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6 · 7 · 8 · 9 · 10 · 11 · 12 · 13 · 14 · 15 · 16 · 17 · 18 · 19 · 20
1 Guideline Consensus Recommendations for the Clinical Application of Repetitive Transcranial Magnetic Stimulation (rTMS) in the Treatment of Depression. 2018

McClintock, Shawn M / Reti, Irving M / Carpenter, Linda L / McDonald, William M / Dubin, Marc / Taylor, Stephan F / Cook, Ian A / O'Reardon, John / Husain, Mustafa M / Wall, Christopher / Krystal, Andrew D / Sampson, Shirlene M / Morales, Oscar / Nelson, Brent G / Latoussakis, Vassilios / George, Mark S / Lisanby, Sarah H / Anonymous3580907 / Anonymous3590907. ·Department of Psychiatry, UT Southwestern Medical Center, 5323 Harry Hines Blvd, Dallas, TX 75390-8898. shawn.mcclintock@utsouthwestern.edu. · Department of Psychiatry, UT Southwestern Medical Center, Dallas, Texas, USA. · Division of Brain Stimulation and Neurophysiology, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina, USA. · Department of Psychiatry and Behavioral Sciences, The Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. · Butler Hospital, Brown Department of Psychiatry and Human Behavior, Providence, Rhode Island, USA. · Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia, USA. · Department of Psychiatry, Weill Cornell Medical College, White Plains, New York, USA. · Department of Psychiatry, University of Michigan, Ann Arbor, Michigan, USA. · Semel Institute for Neuroscience and Human Behavior, Departments of Psychiatry and Behavioral Sciences and of Bioengineering, University of California at Los Angeles, Los Angeles, California, USA. · Department of Psychiatry and Behavioral Sciences, Rowan University School of Medicine, Stratford, New Jersey, USA. · PrarieCare, Rochester, Minnesota, USA. · Department of Psychiatry, University of California San Francisco School of Medicine, San Francisco, California, USA. · Department of Psychiatry and Psychology, Mayo Clinic, Rochester, Minnesota, USA. · Psychiatric Neurotherapeutics Program, McLean Hospital, Harvard Medical School, Boston, Massachusetts, USA. · Department of Psychiatry, University of Minnesota, St Louis Park, Minnesota, USA. · Department of Psychiatry and Behavioral Sciences, Medical University of South Carolina, Charleston, South Carolina, USA. · Ralph H. Johnson VA Medical Center, Charleston, South Carolina, USA. ·J Clin Psychiatry · Pubmed #28541649.

ABSTRACT: OBJECTIVE: To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). PARTICIPANTS: Participants included a group of 17 expert clinicians and researchers with expertise in the clinical application of rTMS, representing both the National Network of Depression Centers (NNDC) rTMS Task Group and the American Psychiatric Association Council on Research (APA CoR) Task Force on Novel Biomarkers and Treatments. EVIDENCE: The consensus statement is based on a review of extensive literature from 2 databases (OvidSP MEDLINE and PsycINFO) searched from 1990 through 2016. The search terms included variants of major depressive disorder and transcranial magnetic stimulation. The results were limited to articles written in English that focused on adult populations. Of the approximately 1,500 retrieved studies, a total of 118 publications were included in the consensus statement and were supplemented with expert opinion to achieve consensus recommendations on key issues surrounding the administration of rTMS for MDD in clinical practice settings. CONSENSUS PROCESS: In cases in which the research evidence was equivocal or unclear, a consensus decision on how rTMS should be administered was reached by the authors of this article and is denoted in the article as "expert opinion." CONCLUSIONS: Multiple randomized controlled trials and published literature have supported the safety and efficacy of rTMS antidepressant therapy. These consensus recommendations, developed by the NNDC rTMS Task Group and APA CoR Task Force on Novel Biomarkers and Treatments, provide comprehensive information for the safe and effective clinical application of rTMS in the treatment of MDD.

2 Guideline Screening for Depression in Adults: US Preventive Services Task Force Recommendation Statement. 2016

Siu, Albert L / Anonymous2070856 / Bibbins-Domingo, Kirsten / Grossman, David C / Baumann, Linda Ciofu / Davidson, Karina W / Ebell, Mark / García, Francisco A R / Gillman, Matthew / Herzstein, Jessica / Kemper, Alex R / Krist, Alex H / Kurth, Ann E / Owens, Douglas K / Phillips, William R / Phipps, Maureen G / Pignone, Michael P. ·Mount Sinai School of Medicine, New York2James J. Peters Veterans Affairs Medical Center, Bronx, New York. · University of California, San Francisco. · Group Health Research Institute, Seattle, Washington. · University of Wisconsin, Madison. · Columbia University, New York, New York. · University of Georgia, Athens. · Pima County Department of Health, Tucson, Arizona. · Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts. · Independent consultant, Washington, DC. · Duke University, Durham, North Carolina. · Fairfax Family Practice, Fairfax, Virginia13Virginia Commonwealth University, Richmond. · New York University, New York. · Veterans Affairs Palo Alto Health Care System, Palo Alto, California16Stanford University, Stanford, California. · University of Washington, Seattle. · Brown University, Providence, Rhode Island. · University of North Carolina, Chapel Hill. ·JAMA · Pubmed #26813211.

ABSTRACT: DESCRIPTION: Update of the 2009 US Preventive Services Task Force (USPSTF) recommendation on screening for depression in adults. METHODS: The USPSTF reviewed the evidence on the benefits and harms of screening for depression in adult populations, including older adults and pregnant and postpartum women; the accuracy of depression screening instruments; and the benefits and harms of depression treatment in these populations. POPULATION: This recommendation applies to adults 18 years and older. RECOMMENDATION: The USPSTF recommends screening for depression in the general adult population, including pregnant and postpartum women. Screening should be implemented with adequate systems in place to ensure accurate diagnosis, effective treatment, and appropriate follow-up. (B recommendation).

3 Editorial Editorial: Molecular Mechanisms in Stress and Trauma Related Disorders. 2020

Zannas, Anthony S / Stein, Murray B / Chrousos, George P. ·Department of Psychiatry, University of North Carolina, Chapel Hill, NC, United States. · Department of Genetics, University of North Carolina, Chapel Hill, NC, United States. · Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC, United States. · Institute for Trauma Recovery, University of North Carolina School of Medicine, Chapel Hill, NC, United States. · Department of Family Medicine & Public Health, University of California, San Diego, La Jolla, CA, United States. · Department of Psychiatry, University of California, San Diego, La Jolla, CA, United States. · University Research Institute of Maternal and Child Health & Precision Medicine, National and Kapodistrian University of Athens, Athens, Greece. · Center for Adolescent Medicine and UNESCO Chair on Adolescent Health Care, First Department of Pediatrics, School of Medicine, National and Kapodistrian University of Athens, Aghia Sophia Children's Hospital, Athens, Greece. ·Front Psychiatry · Pubmed #32194451.

ABSTRACT: -- No abstract --

4 Editorial Do We Ever Outlive Depression? 2017

Blazer, Dan. ·Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC. Electronic address: dan.g.blazer@dm.duke.edu. ·Am J Geriatr Psychiatry · Pubmed #28826963.

ABSTRACT: -- No abstract --

5 Editorial Do We Ever Escape the Consequences of Childhood Deprivation? 2016

Blazer, Dan G. ·Duke University Medical Center, Durham, NC. Electronic address: dan.g.blazer@dm.duke.edu. ·Am J Geriatr Psychiatry · Pubmed #27569266.

ABSTRACT: -- No abstract --

6 Editorial The brave new world of healthcare delivery: just where are we in our understanding of e-health methods for insomnia and depression management? 2015

Edinger, Jack D. ·Division of Pulmonology, Critical Care and Sleep Medicine, Department of Medicine, National Jewish Health, Denver, CO; Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Durham, NC. ·Sleep · Pubmed #25581925.

ABSTRACT: -- No abstract --

7 Editorial Late life depression: a historical perspective upon a maturing field of inquiry. 2014

Blazer, Dan G. ·a JP Gibbons Professor Department of Psychiatry and Behavioral Sciences , Duke University Medical Center , Durham , NC , USA. ·Aging Ment Health · Pubmed #24824508.

ABSTRACT: -- No abstract --

8 Review Depression and Cognitive Control across the Lifespan: a Systematic Review and Meta-Analysis. 2020

Dotson, Vonetta M / McClintock, Shawn M / Verhaeghen, Paul / Kim, Joseph U / Draheim, Amanda A / Syzmkowicz, Sarah M / Gradone, Andrew M / Bogoian, Hannah R / Wit, Liselotte De. ·Department of Psychology, Georgia State University, P.O. Box 5010, Atlanta, GA, 30302-5010, USA. vdotson1@gsu.edu. · Gerontology Institute, Georgia State University, Atlanta, GA, USA. vdotson1@gsu.edu. · Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA. · Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC, USA. · School of Psychology, Georgia Institute of Technology, Atlanta, GA, USA. · Department of Psychiatry, University of Utah School of Medicine, Lake City, UT, USA. · Department of Psychology, Georgia State University, P.O. Box 5010, Atlanta, GA, 30302-5010, USA. · Department of Neurological Services, University of Nebraska Medical Center, Omaha, NE, USA. · Department of Clinical and Health Psychology, University of Florida, Gainesville, FL, USA. ·Neuropsychol Rev · Pubmed #32385756.

ABSTRACT: Depression has been shown to negatively impact neurocognitive functions, particularly those governed by fronto-subcortical networks, such as executive functions. Converging evidence suggests that depression-related executive dysfunction is greater at older ages, however, this has not been previously confirmed by meta-analysis. We performed a systematic review and meta-analysis, using three-level models, on peer-reviewed studies that examined depression-related differences in cognitive control in healthy community-dwelling individuals of any age. We focused on studies of cognitive control as defined by the National Institute of Mental Health (NIMH) Research Domain Criteria (RDoC) framework, which centers on goal-directed behavior, such as goal selection (updating, representations, maintenance), response selection (inhibition or suppression), and performance monitoring. In 16,806 participants aged 7 to 97 across 76 studies, both clinical depression and subthreshold depressive symptoms were associated with cognitive control deficits (Hedges' g = -0.31). This relationship was stronger in study samples with an older mean age. Within studies with a mean age of 39 years or higher, which represents the median age in our analyses, the relationship was stronger in clinical compared to subthreshold depression and in individuals taking antidepressant medication. These findings highlight the importance of clinicians screening for cognitive control dysfunction in patients with depression, particularly in later stages of adulthood.

9 Review Depression and Cardiovascular Disorders in the Elderly. 2020

Jiang, Wei. ·Department of Psychiatry and Behavioral Sciences, Duke University Health System, Durham, NC 27710, USA; Department of Medicine, Duke University Health System, Durham, NC 27710, USA. Electronic address: jiang001@mc.duke.edu. ·Clin Geriatr Med · Pubmed #32222297.

ABSTRACT: The world's older population continues to grow at an unprecedented rate. This trend amplifies the necessity of improving the care of older patients with chronic health problems. Of those with chronic health problems, those with cardiovascular diseases and depression are particularly challenging due to the multifaceted nature of these conditions. This review discusses the significance of this aging trend and ways to better care for this particular population.

10 Review Hearing Loss: The Silent Risk for Psychiatric Disorders in Late Life. 2020

Blazer, Dan G. ·JP Gibbons Professor Emeritus of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3003, 3521 Hosp South, Durham, NC 27710, USA. Electronic address: dan.g.blazer@dm.duke.edu. ·Clin Geriatr Med · Pubmed #32222296.

ABSTRACT: Hearing loss is among the most frequent problems experienced by older adults, yet psychiatrists and other clinicians often ignore the problem as an aggravation rather than recognizing that the problem might benefit from appropriate hearing health care. Many psychiatric disorders have been associated with hearing loss, including depression, schizophrenia and other psychoses, anxiety, and neurocognitive disorders. In this article, hearing loss among older adults is reviewed, with special attention directed toward the recognition and proper referral to a hearing health care provider. Finally, major advances in hearing health care are discussed.

11 Review The identification, assessment and management of difficult-to-treat depression: An international consensus statement. 2020

McAllister-Williams, R H / Arango, C / Blier, P / Demyttenaere, K / Falkai, P / Gorwood, P / Hopwood, M / Javed, A / Kasper, S / Malhi, G S / Soares, J C / Vieta, E / Young, A H / Papadopoulos, A / Rush, A J. ·Northern Centre for Mood Disorders, Newcastle University, UK; Cumbria, Northumberland, Tyne and Wear NHS Foundation Trust, Newcastle upon Tyne, UK. Electronic address: hamish.mcallister-williams@newcastle.ac.uk. · Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón (IiSGM), CIBERSAM, School of Medicine, Universidad Complutense, Madrid, Spain. · Royal Ottawa Institute of Mental Health Research, University of Ottawa, Canada. · University Psychiatric Center KU Leuven, Faculty of Medicine KU Leuven, Belgium. · Clinic for Psychiatry and Psychotherapy, Ludwig Maximilian University, Munich, Germany. · CMME, Hopital Sainte-Anne (GHU Paris et Neurosciences). Paris-Descartes University, INSERM U1266, Paris, France. · University of Melbourne, Melbourne, Australia. · Faculty of the University of Warwick, UK. · Department of Psychiatry and Psychotherapy, Medical University of Vienna, Austria. · The University of Sydney, Faculty of Medicine and Health, Northern Clinical School, Department of Psychiatry, Sydney, New South Wales, Australia; Academic Department of Psychiatry, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW 2065 Australia; CADE Clinic, Royal North Shore Hospital, Northern Sydney Local Health District, St Leonards, NSW 2065 Australia. · University of Texas Health Science Center, Houston, TX, USA. · Hospital Clinic, Institute of Neuroscience, University of Barcelona, IDIBAPS, CIBERSAM, Barcelona, Catalonia, Spain. · Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience, King's College London & South London and Maudsley NHS Foundation Trust, UK. · Somerset Partnership NHS Foundation Trust, UK. · Duke University School of Medicine, Durham, NC, USA; Texas Tech University Health Sciences Center, Permian Basin, Midland, TX, USA; Duke-NUS Medical School, Singapore. ·J Affect Disord · Pubmed #32217227.

ABSTRACT: BACKGROUND: Many depressed patients are not able to achieve or sustain symptom remission despite serial treatment trials - often termed "treatment resistant depression". A broader, perhaps more empathic concept of "difficult-to-treat depression" (DTD) was considered. METHODS: A consensus group discussed the definition, clinical recognition, assessment and management implications of the DTD heuristic. RESULTS: The group proposed that DTD be defined as "depression that continues to cause significant burden despite usual treatment efforts". All depression management should include a thorough initial assessment. When DTD is recognized, a regular reassessment that employs a multi-dimensional framework to identify addressable barriers to successful treatment (including patient-, illness- and treatment-related factors) is advised, along with specific recommendations for addressing these factors. The emphasis of treatment, in the first instance, shifts from a goal of remission to optimal symptom control, daily psychosocial functional and quality of life, based on a patient-centred approach with shared decision-making to enhance the timely consideration of all treatment options (including pharmacotherapy, psychotherapy, neurostimulation, etc.) to optimize outcomes when sustained remission is elusive. LIMITATIONS: The recommended definition and management of DTD is based largely on expert consensus. While DTD would seem to have clinical utility, its specificity and objectivity may be insufficient to define clinical populations for regulatory trial purposes, though DTD could define populations for service provision or phase 4 trials. CONCLUSIONS: DTD provides a clinically useful conceptualization that implies a search for and remediation of specific patient-, illness- and treatment obstacles to optimizing outcomes of relevance to patients.

12 Review A Critical Review and Synthesis of Clinical and Neurocognitive Effects of Noninvasive Neuromodulation Antidepressant Therapies. 2019

McClintock, Shawn M / Kallioniemi, Elisa / Martin, Donel M / Kim, Joseph U / Weisenbach, Sara L / Abbott, Christopher C. ·Neurocognitive Research Laboratory, Department of Psychiatry, University of Texas (UT) Southwestern Medical Center, Dallas, Texas (McClintock, Kallioniemi, Martin) · Division of Brain Stimulation and Neurophysiology, Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, North Carolina (McClintock) · Black Dog Institute, Sydney, Australia, and School of Psychiatry, University of New South Wales, Sydney (Martin) · Department of Psychiatry, University of Utah School of Medicine, Salt Lake City (Kim, Weisenbach) · VA Salt Lake City, Mental Health Program (Weisenbach) · Department of Psychiatry, University of New Mexico School of Medicine, Albuquerque (Abbott). ·Focus (Am Psychiatr Publ) · Pubmed #31975955.

ABSTRACT: There is a plethora of current and emerging antidepressant therapies in the psychiatric armamentarium for the treatment of major depressive disorder. Noninvasive neuromodulation therapies are one such therapeutic category; they typically involve the transcranial application of electrical or magnetic stimulation to modulate cortical and subcortical brain activity. Although electroconvulsive therapy (ECT) has been used since the 1930s, with the prevalence of major depressive disorder and treatment-resistant depression (TRD), the past three decades have seen a proliferation of noninvasive neuromodulation antidepressant therapeutic development. The purpose of this critical review was to synthesize information regarding the clinical effects, neurocognitive effects, and possible mechanisms of action of noninvasive neuromodulation therapies, including ECT, transcranial magnetic stimulation, magnetic seizure therapy, and transcranial direct current stimulation. Considerable research has provided substantial information regarding their antidepressant and neurocognitive effects, but their mechanisms of action remain unknown. Although the four therapies vary in how they modulate neurocircuitry and their resultant antidepressant and neurocognitive effects, they are nonetheless useful for patients with acute and chronic major depressive disorder and TRD. Continued research is warranted to inform dosimetry, algorithm for administration, and integration among the noninvasive neuromodulation therapies and with other antidepressant strategies to continue to maximize their safety and antidepressant benefit.

13 Review Integration of Palliative Care into Acute Myeloid Leukemia Care. 2019

Webb, Jason A / LeBlanc, Thomas W / El-Jawahri, Areej R. ·Duke Palliative Care, Duke University and Health System, Durham, NC; Department of Medicine, Duke University School of Medicine, Durham, NC; Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine, Durham, NC. Electronic address: Jason.webb@duke.edu. · Department of Medicine, Duke University School of Medicine, Durham, NC; Division of Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC; Duke Cancer Institute, Durham, NC. · Massachusetts General Hospital, Boston, MA; Harvard Medical School, Boston, MA. ·Semin Oncol Nurs · Pubmed #31767262.

ABSTRACT: OBJECTIVE: To provide an overview of the past, present, and future of the integration of palliative care services for patients with hematologic malignancies, such as acute myeloid leukemia (AML). DATA SOURCES: Published literature as indexed in Medline, relevant guideline documents, textbooks, and clinical experience. CONCLUSION: Patients with acute leukemias have substantial palliative care needs that often go unmet with standard oncology care. Evidence shows that the early integration of specialist palliative care into standard oncology care improves patient-centered outcomes among those with advanced solid tumors. Emerging evidence supports similar benefits among hospitalized patients with hematologic malignancies undergoing stem cell transplantation, and additional trials are underway to further test palliative care interventions in patients with AML. IMPLICATIONS FOR NURSING PRACTICE: By better understanding the palliative care needs of patients with AML and the evidence of integration with standard oncologic care, patients with leukemias may be more likely to receive early integrated palliative care.

14 Review Religion, spirituality and depression in prospective studies: A systematic review. 2019

Braam, Arjan W / Koenig, Harold G. ·Department of Humanist Chaplaincy Studies for a Plural Society, University of Humanistic Studies, Utrecht, The Netherlands; Department of Emergency Psychiatry, Department of Residency Training, Altrecht Mental Health Care, Lange Nieuwstraat 119, 3512 PG Utrecht, The Netherlands. Electronic address: a.braam@altrecht.nl. · Department of Psychiatry and Behavioral Sciences, Duke University Medical Center, Box 3400, Durham, NC 27710, USA; Department of Medicine, King Abdulaziz University, Jeddah 21589, Saudi Arabia; School of Public Health, Ningxia Medical University, Yinchuan 750000, PR China. Electronic address: Harold.Koenig@duke.edu. ·J Affect Disord · Pubmed #31326688.

ABSTRACT: BACKGROUND: Many empirical studies have shown inverse associations between measures of religiousness and spirituality (R/S) and depression. Although the majority of these studies is cross-sectional, a considerable number of prospective studies have also appeared. METHODS: The current systematic review offers an overview of the major pattern of associations between the measures of R/S and depression / depressive symptoms in 152 prospective studies (until 2017). RESULTS: With on average two R/S measures per study (excluding measures of religious struggle, treated separately), 49% reported at least one significant association between R/S and better course of depression, 41% showed a non-significant association, and 10% indicated an association with more depression or mixed results. The estimated strength of these associations was modest (d = -0.18). Of the studies that included religious struggle, 59% reported a significant association with more depression (d = +0.30). Especially among persons identified with psychiatric symptoms, R/S was significantly more often protective (d = -0.37). In younger samples and in samples of patients with medical illness, R/S was less often protective. Studies with more extensive adjustment for confounding variables showed significantly more often associations with less depression. Geographical differences in the findings were not present. LIMITATIONS: Given the huge heterogeneity of studies (samples size, duration of follow-up), the current synthesis of evidence is only exploratory. CONCLUSION: In about half of studies, R/S predicted a significant but modest decrease in depression over time. Further inquiry into bi-directional associations between religious struggle and (clinical) depression over time seems warranted.

15 Review Monitoring, prevention and treatment of side effects of long-acting neuraxial opioids for post-cesarean analgesia. 2019

Yurashevich, M / Habib, A S. ·Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA. · Department of Anesthesiology, Duke University School of Medicine, Durham, NC, USA. Electronic address: ashraf.habib@duke.edu. ·Int J Obstet Anesth · Pubmed #31202588.

ABSTRACT: Long-acting neuraxial opioids such as morphine and diamorphine, administered via spinal or epidural routes, are staple components of a multimodal approach to postoperative analgesia following cesarean delivery. The widespread use of neuraxial opioids is due largely to their significant analgesic efficacy and favorable safety profile. The most common side effects of neuraxial opioids are pruritus, nausea and vomiting. These symptoms appear to be dose-related. The most serious complication of neuraxial opioids is respiratory depression, which occurs in 0-0.9% of cases. Hypothermia has also been reported in association with neuraxial morphine use at cesarean delivery. This article will review recent advances in prophylaxis, treatment and monitoring of the side effects of long-acting neuraxial opioids.

16 Review A Review of Novel Antidepressants: A Guide for Clinicians. 2019

Faquih, Amber E / Memon, Raheel I / Hafeez, Hudaisa / Zeshan, Muhammad / Naveed, Sadiq. ·Psychiatry, Dow University of Health Sciences, Karachi, PAK. · Psychiatry, Henry Ford Allegiance Health, Jackson, USA. · Psychiatry, Duke University Health System, Durham, USA. · Psychiatry, Bronx Lebanon Hospital Icahn School of Medicine at Mount Sinai, Bronx, USA. · Psychiatry, Kansas University Medical Center, Kansas, USA. ·Cureus · Pubmed #31106085.

ABSTRACT: This review article aims to provide insight into the mechanisms of action, pharmacokinetics, clinical efficacy, safety and tolerability of four novel antidepressants including desvenlafaxine, vortioxetine, vilazodone, and levomilnacipran. Following keywords are used in PubMed and Scopus to search for relevant articles: (depression) AND (psychopharmacology OR desvenlafaxine OR levomilnacipran OR vortioxetine OR vilazodone). Patients with a lack of effectiveness or tolerability to certain antidepressants may get benefit from selecting a new antidepressant with different mechanism of action. These medications can be an option in the selection of newer antidepressants. Depression may not be caused by the simple deficiency of serotonin in the brain, but rather a complex interplay of various neurotransmitters including serotonin, norepinephrine, glutamate, and histamine at certain brain areas. The above-mentioned novel antidepressants exert their therapeutic benefits by acting on multiple neurotransmitters. The complexity of underlying the neurobiological mechanism should be considered while formulating a plan of care.

17 Review The assessment of resistance to antidepressant treatment: Rationale for the Antidepressant Treatment History Form: Short Form (ATHF-SF). 2019

Sackeim, Harold A / Aaronson, Scott T / Bunker, Mark T / Conway, Charles R / Demitrack, Mark A / George, Mark S / Prudic, Joan / Thase, Michael E / Rush, A John. ·Departments of Psychiatry and Radiology, Columbia University, New York, NY, USA. Electronic address: has1@columbia.edu. · Sheppard Pratt Health System and Department of Psychiatry, University of Maryland, Baltimore, MD, USA. · LivaNova PLC, Houston, TX, USA. · Department of Psychiatry, Washington University, St. Louis, MO, USA. · Trevena, Inc., Chesterbrook, PA, USA. · Departments of Psychiatry, Neurology, and Neuroscience, Medical University of South Carolina, Charleston, SC, USA. · New York State Psychiatric Institute and Department of Psychiatry, Columbia University, New York, NY, USA. · Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA. · Duke-NUS Medical School, Singapore; Duke University, Durham, NC, USA; Texas Tech University, Permian Basin, TX, USA. ·J Psychiatr Res · Pubmed #30974339.

ABSTRACT: There is considerable diversity in how treatment-resistant depression (TRD) is defined. However, every definition incorporates the concept that patients with TRD have not benefited sufficiently from one or more adequate trials of antidepressant treatment. This review examines the issues fundamental to the systematic evaluation of antidepressant treatment adequacy and resistance. These issues include the domains of interventions deemed effective in treatment of major depressive episodes (e.g., pharmacotherapy, brain stimulation, and psychotherapy), the subgroups of patients for whom distinct adequacy criteria are needed (e.g., bipolar vs. unipolar depression, psychotic vs. nonpsychotic depression), whether trials should be rated dichotomously as adequate or inadequate or on a potency continuum, whether combination and augmentation strategies require specific consideration, and the criteria used to evaluate the adequacy of treatment delivery (e.g., dose, duration), trial adherence, and clinical outcome. This review also presents the Antidepressant Treatment History Form: Short-Form (ATHF-SF), a completely revised version of an earlier instrument, and details how these fundamental issues were addressed in the ATHF-SF.

18 Review Burnout in Cardiothoracic Anesthesiology-Expert Perspectives in the Contemporary Era. 2019

Brakke, Tara / Thompson, Annemarie / Shillcutt, Sasha K / Augoustides, John G. ·Department of Anesthesiology, University of Nebraska, Omaha, NE. · Divisions of Cardiothoracic Anesthesia and Critical Care, Department of Anesthesiology, Duke University, Durham, NC. · Department of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA. Electronic address: yiandoc@hotmail.com. ·J Cardiothorac Vasc Anesth · Pubmed #30704827.

ABSTRACT: -- No abstract --

19 Review Psychiatric Care of the Post-September 11 Combat Veteran: A Review. 2019

Johnson, Justin M / Capehart, Bruce P. ·Durham VA Medical Center (J.M.J., B.P.C.), Duke University School of Medicine, Durham, NC 27705. Electronic address: Justin.m.johnson@duke.edu. · Durham VA Medical Center (J.M.J., B.P.C.), Duke University School of Medicine, Durham, NC 27705. ·Psychosomatics · Pubmed #30580807.

ABSTRACT: BACKGROUND: Post-September 11, 2001 combat veterans represent a growing cohort of patients with unique mental health needs, particularly around post-traumatic stress disorder (PTSD) and traumatic brain injury (TBI). The United States (US) remains engaged in conflicts around the globe, so this patient cohort will continue to grow in number. With around 40% of American combat veterans from Iraq and Afghanistan seeking mental health care outside of the Veterans Affairs, understanding the psychiatric needs of the post-September 11 combat veteran is an important goal for all psychiatrists. These patients are relevant to consultation-liaison (C-L) psychiatrists because of their high comorbidity of conditions such as TBI, obstructive sleep apnea, insomnia, and chronic pain. This article reviews the current literature on mental health care for the post-September 11 combat veteran, emphasizing PTSD and TBI treatment, and culling evidence-based recommendations from randomized controlled trials of combat veterans. Emphasis is also placed on the Veterans Affairs/Department of Defense Clinical Practice Guidelines. The authors also bring unique clinical expertise of having served on active duty as psychiatrists for the US Army, including in a combat zone, and both currently work in a Veterans Affairs Iraq and Afghanistan combat veteran mental health clinic. OBJECTIVE: This review outlines useful treatment approaches for PTSD and TBI and briefly covers the comorbid conditions of major depression, chronic pain, and substance use disorders. This review will prepare C-L psychiatrists to care for this challenging patient cohort.

20 Review Difficult-to-treat depression: A clinical and research roadmap for when remission is elusive. 2019

Rush, Augustus John / Aaronson, Scott T / Demyttenaere, Koen. ·1 Duke-National University of Singapore Medical School, Singapore. · 2 Department of Psychiatry & Behavioral Sciences, Duke University, School of Medicine, Durham, NC, USA. · 3 Department of Psychiatry, Texas Tech University Health Sciences Center, Lubbock, TX, USA. · 4 Clinical Research Programs, Sheppard Pratt Health System, Baltimore, MD, USA. · 5 Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA. · 6 University Psychiatric Centre, University of Leuven, Leuven, Belgium. · 7 Faculty of Medicine, Department of Neurosciences, Research Group Psychiatry, University of Leuven, Leuven, Belgium. ·Aust N Z J Psychiatry · Pubmed #30378447.

ABSTRACT: OBJECTIVES: The report considers the pros and cons of the most commonly used conceptual model that forms the basis for most clinical practice guidelines for depression. This model promotes the attainment of sustained symptom remission as the treatment goal based on its well-established prognostic and functional importance. Sustained remission is very unlikely, however, after multiple treatment attempts. Our current model propels many clinicians to continue to change or add treatments despite little chance for remission or full functional restoration and despite the increasing risk of more adverse events from polypharmacy. An alternative 'difficult-to-treat depression' model is presented and considered. It accepts that the treatment aims for some depressed patients may shift to optimal symptom control rather than remission. When difficult-to-treat depression is suspected, the many treatable causes of persistent depression must be assessed and addressed (given the importance of remission when attainable) before difficult-to-treat depression can be ascribed. The clinical and research implications of the difficult-to-treat depression model are discussed. CONCLUSION: Suspected difficult-to-treat depression provides a practical basis for considering when to conduct a comprehensive evaluation. Once difficult-to-treat depression is confirmed, treatment may better focus on optimal disease management (symptom control and functional improvement).

21 Review Algorithms For Treatment of Major Depressive Disorder: Efficacy and Cost-Effectiveness. 2019

Bauer, Michael / Rush, A John / Ricken, Roland / Pilhatsch, Maximilian / Adli, Mazda. ·Department of Psychiatry and Psychotherapy, University Hospital Carl Gustav Carus, Medical Faculty, Technische Universität Dresden, Dresden, Germany. · Duke-National University of Singapore, Singapore. · Department of Psychiatry, Duke University Medical School, Durham, NC, USA. · Department of Psychiatry, Texas Tech Health Science Center, Permian Basin, TX, USA. · Department of Psychiatry and Psychotherapy, Charité - Universitätsmedizin Berlin, Campus Mitte, Germany. · Fliedner Klinik Berlin, Center for Psychiatry, Psychotherapy and Psychosomatic Medicine, Berlin, Germany. ·Pharmacopsychiatry · Pubmed #29986372.

ABSTRACT: In spite of multiple new treatment options, chronic and treatment refractory courses still are a major challenge in the treatment of depression. Providing algorithm-guided antidepressant treatments is considered an important strategy to optimize treatment delivery and avoid or overcome treatment-resistant courses of major depressive disorder (MDD). The clinical benefits of algorithms in the treatment of inpatients with MDD have been investigated in large-scale, randomized controlled trials. Results showed that a stepwise treatment regimen (algorithm) with critical decision points at the end of each treatment step based on standardized and systematic measurements of response and an algorithm-guided decision-making process increases the chances of achieving remission and optimizes prescription behaviors for antidepressants. In conclusion, research in MDD revealed that systematic and structured treatment procedures, the diligent assessment of response at critical decision points, and timely dose and treatment type adjustments make the substantial difference in treatment outcomes between algorithm-guided treatment and treatment as usual.

22 Review When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips. 2018

Jha, Manish K / Rush, A John / Trivedi, Madhukar H. ·From the Center for Depression Research and Clinical Care, University of Texas Southwestern Medical Center, Dallas; Duke-National University of Singapore, Singapore; the Department of Psychiatry, Duke University Medical School, Durham, N.C.; and Texas Tech Health Sciences Center-Permian Basin, Midland-Odessa. ·Am J Psychiatry · Pubmed #30501420.

ABSTRACT: -- No abstract --

23 Review Improving Depression Outcome by Patient-Centered Medical Management. 2018

Rush, A John / Thase, Michael E. ·From the Duke-National University of Singapore Graduate Medical School, Singapore; the Department of Psychiatry, Duke University Medical School, Durham, N.C.; the Department of Psychiatry, Texas Tech Health Sciences Center-Permian Basin, Midland-Odessa; the Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia; and the Corporal Michael J. Crescenz VA Medical Center, Philadelphia. ·Am J Psychiatry · Pubmed #30220219.

ABSTRACT: Specific challenges that profoundly affect the outcome of treatment for depression include 1) patient engagement and retention in care and optimization of treatment adherence, 2) optimization of symptom and side effect control by medication adjustments using measurement-based care procedures, 3) restoration of daily functioning and quality of life, and 4) prevention or at least mitigation of symptomatic relapse or recurrence. According to data from the Sequenced Treatment Alternatives to Relieve Depression study, some 10%-15% of patients will not return for treatment after an initial thorough evaluation visit; an additional 20%-35% will not complete the first acute-phase treatment step, and another 20%-50% will not complete 6 months of continuation treatment. Among patients who stay in treatment, over 50% exhibit poor adherence. Thus, most patients do not overcome the first two challenges. There are no systematic, widely agreed-upon psychosocial approaches to any of these four major challenges. The authors propose "patient-centered medical management" to address each of the four challenges, using psychoeducational, behavioral, cognitive, interpersonal, and dynamic models and methods. A renewed emphasis on the development and testing of systematic approaches to overcoming these common clinical challenges could enhance the chances of patient recovery and care system cost efficiencies. [AJP AT 175: Remembering Our Past As We Envision Our Future July 1933: Psychotherapeutics at Stockbridge Horace K. Richardson: "Frequently, in the simpler situations, very few interviews are required in order that he [the patient] discover for himself what part of the adaptive machinery is at fault, and for him to develop a technique of handling the maladjustment on a more satisfactory level in the future." (Am J Psychiatry 1933; 90:45-56 )].

24 Review Chest Pain: If It Is Not the Heart, What Is It? 2018

Rushton, Sharron / Carman, Margaret J. ·Duke University School of Nursing, DUMC Box 3322, Durham, NC 27710, USA. Electronic address: Sharron.Rushton@duke.edu. · Georgetown University School of Nursing and Health Studies, St. Mary's Hall, 3700 Reservoir Road Northwest, Washington, DC 20007, USA. ·Nurs Clin North Am · Pubmed #30100007.

ABSTRACT: Noncardiac chest pain is an angina-type discomfort without indication of ischemia. Diagnosis can be difficult because of its heterogeneous nature. Classification varies by specialty; gastroenterology uses the terminology gastroesophageal reflux disease related versus non-gastroesophageal reflux disease related. Other disciplines recognize noncardiac chest pain etiologies as having gastrointestinal, musculoskeletal, psychiatric, or pulmonary/other as underlying etiologies. Diagnostics yield a specific cause for effective treatment, which is aimed at the underlying etiology, but it is not always possible. Some patients with noncardiac chest pain have comorbidities and ongoing pain that lead to decreased quality of life and continued health care use.

25 Review Psychosocial Aspects of Fertility and Assisted Reproductive Technology. 2018

Stanhiser, Jamie / Steiner, Anne Z. ·Reproductive Endocrinology and Infertility, University of North Carolina, Chapel Hill, NC, USA. Electronic address: jamie_stanhiser@med.unc.edu. · Duke University Hospital, 2301 Erwin Road, Durham, NC 27710, USA. ·Obstet Gynecol Clin North Am · Pubmed #30092929.

ABSTRACT: Psychosocial aspects of fertility, infertility, and assisted reproductive technology (ART) can significantly impact patients' sense of self-identity and personal agency, mental well-being, sexual and marital relationships, reproductive efficiency, compliance with treatment, and pregnancy outcomes. Research is needed to understand how stress, anxiety, depression, mood disorders, and psychotropic medications impact fertility and infertility treatment. The psychosocial implications of ART on our society include a shift toward older maternal age at conception, the complexities of third-party reproduction, and consideration for the psychological and socioeconomic barriers to receiving care. Clinicians must understand, screen for, and identify couples struggling with the psychological and social aspects of fertility and ART.

Next